Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has shared an update.
China Resources Pharmaceutical Group Limited has announced that its non-wholly owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd., has obtained registration approval from the China Securities Regulatory Commission to issue up to RMB3 billion in corporate bonds to qualified investors in mainland China over the next 24 months. The potential bond issuance, which may be carried out in tranches and is not yet certain to proceed, would give the subsidiary additional financing flexibility that could support its operational and strategic needs, with implications for the group’s capital structure and funding options, although investors are cautioned about the uncertainty of the transaction’s completion.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company with operations in mainland China through various subsidiaries, including its non-wholly owned unit China Resources Double-Crane Pharmaceutical Co., Ltd. The group is engaged in the pharmaceutical sector, focusing on the production, distribution and related healthcare businesses within the Chinese market.
YTD Price Performance: 3.37%
Average Trading Volume: 12,885,484
Technical Sentiment Signal: Sell
Current Market Cap: HK$28.9B
For an in-depth examination of 3320 stock, go to TipRanks’ Overview page.